Shattuck Labs (STTK) Stock Analysis

What Shattuck Labs does

Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.

Key metrics

ETFs linked to STTK

Broad-market and Healthcare sector ETFs an investor holding Shattuck Labs is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how STTK fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Shattuck Labs?

Shattuck Labs trades under the ticker STTK on NASDAQ.

Which exchange is STTK listed on?

STTK is listed on NASDAQ.

What sector does Shattuck Labs operate in?

Shattuck Labs is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze STTK in a portfolio?

PortView shows STTK's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.